Australia's most trusted
source of pharma news
Friday, 12 December 2025
Posted 11 December 2025 PM
Mayne Pharma has terminated the Scheme Implementation Deed with US-based Cosette, bringing to an official end the planned $672 million sale of the Aussie company - but the saga looks like it could roll on.
In an ASX announcement this morning, Mayne said it would not be paying a "break fee" for bringing the drama-filled failed acquisition to a close and hinted there could be more legal action.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.